As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
6 Analysts have issued a Exicure Inc forecast:
6 Analysts have issued a Exicure Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -8.21 -8.21 |
22%
22%
|
EBIT (Operating Income) EBIT | -8.35 -8.35 |
21%
21%
|
Net Profit | -7.88 -7.88 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Head office | United States |
CEO | Andy Yoo |
Employees | 7 |
Founded | 2011 |
Website | www.exicuretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.